Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5P3SI
|
|||
| Drug Name |
STP1002
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
ST Pharm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tankyrase (TNKS) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04505839) First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.